News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Laboratory Corporation of America Holdings (LabCorp) (LH) Introduces HCV Resistance Testing through Monogram Biosciences (MGRM) with the Launch of HCV GenoSure® NS3/4A



8/25/2011 10:30:06 AM

BURLINGTON, N.C.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced today the nationwide availability of a nucleic acid sequencing assay that reports NS3 and NS4A mutations and NS3 associated resistance to the recently approved hepatitis C virus (HCV) protease inhibitors, adding to LabCorp’s suite of HCV testing. Identification of certain mutations may be useful to clinicians considering patient treatment decisions.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES